The project will commence in January 2024 and is led by principal investigators Louise Klem (Senior Research Scientist) and Anders Nykjær (CSO and founder).
The grant was awarded under the MJFF’s Parkinson’s Disease Therapeutics Pipeline Program (preclinical).
The programme seeks to advance preclinical testing of promising therapeutic developments that address unmet medical needs in people with Parkinson’s disease.
The programme is set up to fund therapeutic development with a clear focus to prevent, stop or delay disease progression or to reduce the challenges of daily symptoms.
Vesper is currently expediting the development of VES001 for FTD(GRN) through ongoing Phase I studies that will include a Phase Ib Proof-of Concept in GRN mutation carriers in advance of potentially registrational Phase II/III trials, and for Phase I readiness of VES002, a treatment focused on a second central nervous system indication.
Anders Nykjaer, Chief Scientific Officer of Vesper Bio, commented; “Vesper has developed orally administered, small molecule, sortilin inhibitors that elevate central progranulin levels and these hold promise for treating certain CNS diseases, including Parkinson’s disease."
"This grant by The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Pipeline Program will support our research as we look to further demonstrate the efficacy of this novel therapy against this terrible disease.”
Jessica Tome Garcia, Associate Director, Translational Research at MJFF, said: “MJFF greatly values research into the biological underpinnings of Parkinson’s disease and leveraging that insight for new treatment ideas."
"We are proud to fund the work of researchers at Vesper Bio as they investigate new ways to fulfil the unmet needs of people with Parkinson’s.”
